This study tests different doses of a new medicine, **BI 1569912**, for people with depression who are already taking anti-depressive medicine. Depression is a mental health issue that makes people feel very sad. The study is for adults aged 18 to 65 who have a type of depression called *major depressive disorder* (MDD) and haven’t been helped by other treatments.
Participants are randomly placed into one of four groups. Three groups take different doses of BI 1569912, and one group takes a *placebo* (a pill that looks like the medicine but has no active ingredients). The study lasts about 2 to 4 and a half months, with participants taking a pill daily for 6 weeks and visiting the study site at least six times for check-ups.
The study aims to see if BI 1569912 improves depression symptoms, with doctors monitoring participants' health throughout.
- Study duration: 2 to 4.5 months with 6 site visits.
- Random assignment to medicine or placebo group.
- Participants continue their regular depression treatment.